Gene Therapy LYS-SAF302 Continuing to Help Sanfilippo Type A Children in Trial
Editor’s Note: This story was updated on March 24, 2021, to include information about setbacks and safety concerns related to the AAVance trial. LYS-SAF302, Lysogene’s experimental gene therapy for Sanfilippo syndrome type A, effectively lowered the levels of three disease biomarkers — GM2, GM3, and heparan sulfate…